RecruitingNCT03223077
Mucosal and Microbiota Changes During Acute Campylobacteriosis
Sponsor
Mayo Clinic
Enrollment
150 participants
Start Date
Oct 31, 2014
Study Type
OBSERVATIONAL
Conditions
Summary
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- No abdominal surgery (except appendectomy and cholecystectomy)
- Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter
Exclusion Criteria3
- History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease.
- History of gastroenteritis in six months prior to Campylobacter enteritis
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03223077
Related Trials
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
NCT059723171 location
Psyllium in Pediatric IBS
NCT066399841 location
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT0754575988 locations
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
NCT062715381 location
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT075457721 location